326 related articles for article (PubMed ID: 9843170)
41. Total joint replacement in patients with inhibitors.
Solimeno LP; Perfetto OS; Pasta G; Santagostino E
Haemophilia; 2006 Jul; 12 Suppl 3():113-6. PubMed ID: 16684005
[TBL] [Abstract][Full Text] [Related]
42. Optimal care of inhibitor patients during surgery.
Vermylen J; Peerlinck K
Eur J Haematol Suppl; 1998; 63():15-7. PubMed ID: 9882927
[TBL] [Abstract][Full Text] [Related]
43. Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.
Dunkley S; Phillips L; McCall P; Brereton J; Lindeman R; Jankelowitz G; Cameron P
Ann Thorac Surg; 2008 Mar; 85(3):836-44. PubMed ID: 18291152
[TBL] [Abstract][Full Text] [Related]
44. How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.
Brown SA; Barnes C; Curtin J; Dunkley S; Ockelford P; Phillips J; Rowell J; Smith M; Tran H;
Intern Med J; 2012 Nov; 42(11):1243-50. PubMed ID: 23157518
[TBL] [Abstract][Full Text] [Related]
45. First 20 years with recombinant FVIIa (NovoSeven).
Hedner U; Lee CA
Haemophilia; 2011 Jan; 17(1):e172-82. PubMed ID: 20609014
[TBL] [Abstract][Full Text] [Related]
46. Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial.
Kenet G; Stenmo CB; Blemings A; Wegert W; Goudemand J; Krause M; Schramm W; Kirchmaier C; Martinowitz U
Thromb Haemost; 2010 Feb; 103(2):351-9. PubMed ID: 20024491
[TBL] [Abstract][Full Text] [Related]
47. Key issues in inhibitor management in patients with haemophilia.
Gomez K; Klamroth R; Mahlangu J; Mancuso ME; Mingot ME; Ozelo MC
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s319-29. PubMed ID: 24333092
[No Abstract] [Full Text] [Related]
48. Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection.
Chuansumrit A; Isarangkura P; Angchaisuksiri P; Sriudomporn N; Tanpowpong K; Hathirat P; Jorgensen LN
Haemophilia; 2000 Mar; 6(2):61-5. PubMed ID: 10781189
[TBL] [Abstract][Full Text] [Related]
49. Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX.
Ekert H; Brewin T; Boey W; Davey P; Tilden D
Haemophilia; 2001 May; 7(3):279-85. PubMed ID: 11380632
[TBL] [Abstract][Full Text] [Related]
50. Development of anaphylactic shock in haemophilia B patients with inhibitors.
Warrier I; Lusher JM
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S125-8. PubMed ID: 9819043
[TBL] [Abstract][Full Text] [Related]
51. Use of high dose factor VIIa in hemophilia patients.
Hedner U
Adv Exp Med Biol; 2001; 489():75-88. PubMed ID: 11554593
[No Abstract] [Full Text] [Related]
52. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
Mahasandana C; Patharathienskul D; Suvatte V
Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549
[TBL] [Abstract][Full Text] [Related]
53. [Prospective matched control study concerning the treatment and quality of life of hemophiliacs with inhibitors].
Honda K; Nagao T; Kamiya T; Yoshioka A; Miyazaki T; Takeda T; Mori K; Fukutake K; Hanabusa H; Taki M; Mohri H; Miyama J; Takamatsu J; Kinoshita S; Shirahata A
Rinsho Ketsueki; 1998 Jun; 39(6):416-21. PubMed ID: 9695668
[TBL] [Abstract][Full Text] [Related]
54. Experience of recombinant activated factor VII usage during surgery in patients with haemophilia with inhibitors.
Polyanskaya T; Zorenko V; Karpov E; Sampiev M; Mishin G; Vasiliev D
Haemophilia; 2012 Nov; 18(6):997-1002. PubMed ID: 22672066
[TBL] [Abstract][Full Text] [Related]
55. Thrombelastography-guided factor VIIa therapy in a surgical patient with severe hemophilia and factor VIII inhibitor.
Pivalizza EG; Escobar MA
Anesth Analg; 2008 Aug; 107(2):398-401. PubMed ID: 18633014
[TBL] [Abstract][Full Text] [Related]
56. How to manage invasive procedures in children with haemophilia.
Ljung RC; Knobe K
Br J Haematol; 2012 Jun; 157(5):519-28. PubMed ID: 22390160
[TBL] [Abstract][Full Text] [Related]
57. Early treatment with recombinant factor VIIa results in greater efficacy with less product.
Lusher JM
Eur J Haematol Suppl; 1998; 63():7-10. PubMed ID: 9882925
[TBL] [Abstract][Full Text] [Related]
58. Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia and Thrombosis Research Society Registry (2004-2008).
Nakar C; Cooper DL; DiMichele D
Haemophilia; 2010 Jul; 16(4):625-31. PubMed ID: 20158526
[TBL] [Abstract][Full Text] [Related]
59. Management of haemophilic patients with inhibitors in major orthopaedic surgery by immunadsorption, substitution of factor VIII and recombinant factor VIIa (NovoSeven): a single centre experience.
Habermann B; Hochmuth K; Hovy L; Scharrer I; Kurth AH
Haemophilia; 2004 Nov; 10(6):705-12. PubMed ID: 15569165
[TBL] [Abstract][Full Text] [Related]
60. Effect of activated recombinant human factor 7 (Niastase) on laboratory testing of inhibitors of factors VIII and IX.
Keeney M; Allan DS; Lohmann RC; Yee IH
Lab Hematol; 2005; 11(2):118-23. PubMed ID: 16024335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
